Two phase I study (ALKA-372-001 and STARTRK-1) assessing entrectinib in NTRK-, ROS1-, and ALK-positive solid tumor showed promising efficacy and durable clinical benefit of 32 months in a ROS1-positive lung cancer patients [139]. The gene discussed is ALK; the disease is lung carcinoma.